Related Experiment Videos
Initial results and long-term clinical and angiographic implications of coronary stenting in elderly patients
F Alfonso1, L Azcona, M J Perez-Vizcayno
1Department of Clinical Epidemiology, San Carlos University Hospital, Madrid, Spain.
Insights
Elderly patients (age 65+) undergoing coronary stenting had similar restenosis rates but higher risks of death. Age is a key factor in predicting mortality after this cardiac procedure.
Area of Science:
- Cardiology
- Geriatric Medicine
- Interventional Cardiology
Background:
- Coronary stenting is a common procedure for treating coronary artery disease.
- The safety and efficacy of coronary stenting in elderly populations require further investigation.
Purpose of the Study:
- To compare outcomes of coronary stenting in elderly patients (>= 65 years) versus younger patients.
- To identify predictors of mortality in elderly patients undergoing coronary stenting.
Main Methods:
- Retrospective analysis of 378 elderly patients and 601 younger patients who underwent coronary stenting.
- Comparison of restenosis rates and mortality between the two age groups.
- Statistical analysis to determine independent predictors of mortality.
Main Results:
- Restenosis rates were comparable between elderly and younger patient groups.
- Age >= 65 years was an independent predictor of in-hospital mortality (RR 5.4, 95% CI 1.2-20.1).
- Age >= 65 years was also an independent predictor of follow-up mortality (RR 2.8, 95% CI 1.3-6.1).
Conclusions:
- While restenosis rates are similar, elderly patients undergoing coronary stenting face significantly higher mortality risks.
- Age is a critical independent risk factor for both short-term and long-term mortality following coronary stenting.
Abstract:
Results of 378 consecutive elderly patients (> or = 65 years) undergoing coronary stenting were compared with those of 601 younger patients. Although the restenosis rate was similar in the 2 groups, age > or = 65 years was an independent predictor of in-hospital mortality (relative risk 5.4, 95% confidence interval 1.2 to 20.1) and follow-up mortality (relative risk 2.8, 95% confidence interval 1.3 to 6.1).